Global heart health leader urges Americans to monitor blood pressure regularly and take action to manage hypertension among increased health risks associated with COVID-19 pandemic HOFFMAN ESTATES, Ill., May 5, 2022 /PRNewswire/ — Global heart health leader,, today issued a national health alert warning of increased heart health risks emerging from the […]
Other News
Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter
Single- and dual-lumen biomaterial catheters allow hospitals to reduce thrombosis and vascular access complications for majority of PICC applications BILLERICA, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter. Designed […]
Inari Medical Reports First Quarter 2022 Financial Results
IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022. First Quarter Revenue […]
Eko Recognized with Second Consecutive MedTech Breakthrough Award for AI Innovation in Healthcare
Point-of-care cardiac screening solution honored at sixth annual awards program for improving detection of heart disease OAKLAND, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Eko, a digital health company advancing heart and lung disease detection, today announced that, for the second consecutive year, it has won the “Best Use of Artificial […]
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for […]
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released […]
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or […]
Clarius Receives CE Mark Certification for Seven New Ultra-Portable Wireless Ultrasound Scanners for Apple and Android Devices
Miniaturized to the size of an iPhone, the third-generation ultrasound scanners make high-definition ultrasound affordable for more doctors across specialties in Europe VANCOUVER, British Columbia–(BUSINESS WIRE)–Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter […]
Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results
Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 revenue guidance narrowed to $235 million to $240 million Announced […]
AtriCure Reports First Quarter 2022 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team delivered exceptional first quarter performance, with broad-based growth across all key products,” said Michael Carrel, […]



